FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2805026993> ?p ?o ?g. }

• W2805026993 endingPage "771" @default.
• W2805026993 startingPage "761" @default.
• W2805026993 abstract "The pharmacokinetic properties of mecillinam (MEC) for urinary tract infections are excellent, and the resistance rate in Enterobacteriaceae is low compared to other recommended antibiotics. The oral prodrug pivmecillinam (P-MEC) has been used successfully as first choice for cystitis in the Nordic countries for many years. Norwegian and Danish guidelines also recommend P-MEC for acute uncomplicated pyelonephritis (AUP) and intravenous (IV) MEC for suspected urosepsis (only in Denmark). Here, we wish to present an updated investigation on the clinical data behind these recommendations together with sparse but more current clinical data.Prospective clinical trials evaluating MEC as monotherapy or in polytherapy with one other beta-lactam (mostly ampicillin [AMP]) for pyelonephritis or bacteremia were reviewed. Outcomes of primary interest were clinical and bacteriological success and relapse, respectively. Search databases used were PubMed, Cochrane Library, and Embase.Twelve clinical studies (1979-2015) were included in this integrated literature review. Clinical success was seen in 38/51 (75%) patients treated with MEC as monotherapy and in 152/164 (93%) patients treated with MEC and one other beta-lactam. Bacteriological success was seen in 35/47 (74%) and 117/167 (70%) patients treated with MEC alone and with one other beta-lactam, respectively. In complicated infections, bacteriological success was much lower. Clinical relapse rate was not well described. Several uropathogenic bacteremia cases were treated successfully with MEC alone (ie, 10/15 [67%] and 13/15 [87%] for clinical and bacteriological success, respectively) or with one other beta-lactam (ie, 57/65 [88%] and 53/63 [84%] for clinical and bacteriological success, respectively). However, data on bacteremia are very sparse. Adverse reactions were few and mild (73/406 [18%]) and primarily seen when AMP was co-administered (69/73 [95%]). No serious adverse reactions were reported.IV MEC or oral P-MEC for 14 days may be suitable for the treatment of AUP and pediatric pyelonephritis. Randomized controlled trials using a single standardized dose of P-MEC compared to other current recommendations are warranted. Similarly, more evidence is required before MEC should be recommended for bacteremia or sepsis due to Enterobacteriaceae." @default.
• W2805026993 created "2018-06-01" @default.
• W2805026993 creator A5044280311 @default.
• W2805026993 creator A5060855733 @default.
• W2805026993 creator A5085051687 @default.
• W2805026993 creator A5091599290 @default.
• W2805026993 date "2018-05-01" @default.
• W2805026993 modified "2023-10-12" @default.
• W2805026993 title "Mecillinam for the treatment of acute pyelonephritis and bacteremia caused by Enterobacteriaceae: a literature review" @default.
• W2805026993 cites W1751218378 @default.
• W2805026993 cites W1870367888 @default.
• W2805026993 cites W1977291737 @default.
• W2805026993 cites W1978349835 @default.
• W2805026993 cites W1988408197 @default.
• W2805026993 cites W1996835696 @default.
• W2805026993 cites W2001331351 @default.
• W2805026993 cites W2001543316 @default.
• W2805026993 cites W2007932452 @default.
• W2805026993 cites W2013955149 @default.
• W2805026993 cites W2016520936 @default.
• W2805026993 cites W2046896405 @default.
• W2805026993 cites W2049694574 @default.
• W2805026993 cites W2060561490 @default.
• W2805026993 cites W2071236978 @default.
• W2805026993 cites W2078381544 @default.
• W2805026993 cites W2101077702 @default.
• W2805026993 cites W2104330165 @default.
• W2805026993 cites W2104880949 @default.
• W2805026993 cites W2107655373 @default.
• W2805026993 cites W2108292225 @default.
• W2805026993 cites W2112438603 @default.
• W2805026993 cites W2118336036 @default.
• W2805026993 cites W2119120874 @default.
• W2805026993 cites W2120750073 @default.
• W2805026993 cites W2121470545 @default.
• W2805026993 cites W2123177684 @default.
• W2805026993 cites W2125706071 @default.
• W2805026993 cites W2129143216 @default.
• W2805026993 cites W2136400611 @default.
• W2805026993 cites W2146211108 @default.
• W2805026993 cites W2157560909 @default.
• W2805026993 cites W21610953 @default.
• W2805026993 cites W2436757198 @default.
• W2805026993 cites W2548510546 @default.
• W2805026993 cites W51445915 @default.
• W2805026993 cites W6892229 @default.
• W2805026993 doi "https://doi.org/10.2147/idr.s163280" @default.
• W2805026993 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5973435" @default.
• W2805026993 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29872326" @default.
• W2805026993 hasPublicationYear "2018" @default.
• W2805026993 type Work @default.
• W2805026993 sameAs 2805026993 @default.
• W2805026993 citedByCount "22" @default.
• W2805026993 countsByYear W28050269932019 @default.
• W2805026993 countsByYear W28050269932020 @default.
• W2805026993 countsByYear W28050269932021 @default.
• W2805026993 countsByYear W28050269932022 @default.
• W2805026993 countsByYear W28050269932023 @default.
• W2805026993 crossrefType "journal-article" @default.
• W2805026993 hasAuthorship W2805026993A5044280311 @default.
• W2805026993 hasAuthorship W2805026993A5060855733 @default.
• W2805026993 hasAuthorship W2805026993A5085051687 @default.
• W2805026993 hasAuthorship W2805026993A5091599290 @default.
• W2805026993 hasBestOaLocation W28050269931 @default.
• W2805026993 hasConcept C104317684 @default.
• W2805026993 hasConcept C126322002 @default.
• W2805026993 hasConcept C168563851 @default.
• W2805026993 hasConcept C177713679 @default.
• W2805026993 hasConcept C185592680 @default.
• W2805026993 hasConcept C2776021129 @default.
• W2805026993 hasConcept C2776478404 @default.
• W2805026993 hasConcept C2777894859 @default.
• W2805026993 hasConcept C2778910516 @default.
• W2805026993 hasConcept C2779443120 @default.
• W2805026993 hasConcept C501593827 @default.
• W2805026993 hasConcept C535046627 @default.
• W2805026993 hasConcept C547475151 @default.
• W2805026993 hasConcept C55493867 @default.
• W2805026993 hasConcept C71924100 @default.
• W2805026993 hasConcept C77411442 @default.
• W2805026993 hasConcept C86803240 @default.
• W2805026993 hasConcept C89423630 @default.
• W2805026993 hasConceptScore W2805026993C104317684 @default.
• W2805026993 hasConceptScore W2805026993C126322002 @default.
• W2805026993 hasConceptScore W2805026993C168563851 @default.
• W2805026993 hasConceptScore W2805026993C177713679 @default.
• W2805026993 hasConceptScore W2805026993C185592680 @default.
• W2805026993 hasConceptScore W2805026993C2776021129 @default.
• W2805026993 hasConceptScore W2805026993C2776478404 @default.
• W2805026993 hasConceptScore W2805026993C2777894859 @default.
• W2805026993 hasConceptScore W2805026993C2778910516 @default.
• W2805026993 hasConceptScore W2805026993C2779443120 @default.
• W2805026993 hasConceptScore W2805026993C501593827 @default.
• W2805026993 hasConceptScore W2805026993C535046627 @default.
• W2805026993 hasConceptScore W2805026993C547475151 @default.
• W2805026993 hasConceptScore W2805026993C55493867 @default.
• W2805026993 hasConceptScore W2805026993C71924100 @default.
• W2805026993 hasConceptScore W2805026993C77411442 @default.

• next